32
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

Novel 4-aminopyrazolo[3,4-b]pyridine PDE4 inhibitors

Pages 111-114 | Published online: 22 Apr 2005

Bibliography

  • NORMAN P: PDE4 inhibitors 2001 patent and literature activity 2000- September 2001. Expert Opin. Ther. Patents (2002) 12:93–112.
  • •Recent review focussed on patent activity.
  • VIGNOLA AM: PDE4 inhibitors in COPD - a more selective approach to treatment. Respir. Med. (2004) 98(0:495–503.
  • •Focused on the most likely therapeutic indication of these agents.
  • SPINA D: Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs (2003) 63(23):2575–2594.
  • •Review from an alternative perspective.
  • MONTANA JG, DYKE HJ: Update on the therapeutic potential of PDE4 inhibitors Expert Opin. Investig. Drugs (2002) 11:1–13.
  • •Updated review of recent clinical developments.
  • RENAU TE: The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges. Curr . Opin. Investig. Drugs (2004) 5(1):34–39.
  • HATZELMANN A, SCHUDT C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. (2001) 297(1):267–279.
  • BUNDUSCHUH DS, ELTZE M, BARSIG J et al.: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. (2001) 297(1):280–290.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.